LCTX Stock Overview
A clinical-stage biotechnology company, develops novel cell therapies for unmet medical needs in the United States and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Lineage Cell Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.88 |
| 52 Week High | US$1.61 |
| 52 Week Low | US$0.77 |
| Beta | 1.28 |
| 11 Month Change | -3.09% |
| 3 Month Change | 1.03% |
| 1 Year Change | -17.82% |
| 33 Year Change | -59.48% |
| 5 Year Change | 0.72% |
| Change since IPO | -74.26% |
Recent News & Updates
Shareholder Returns
| LCTX | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -6.9% | -10.3% | -2.1% |
| 1Y | -17.8% | 13.6% | 29.6% |
Return vs Industry: LCTX underperformed the US Biotechs industry which returned 13.6% over the past year.
Return vs Market: LCTX underperformed the US Market which returned 29.6% over the past year.
Price Volatility
| LCTX volatility | |
|---|---|
| LCTX Average Weekly Movement | 7.7% |
| Biotechs Industry Average Movement | 9.8% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in US Market | 15.5% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: LCTX has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: LCTX's weekly volatility (8%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1990 | 72 | Brian Culley | www.lineagecell.com |
Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, develops novel cell therapies for unmet medical needs in the United States and internationally. The company develops OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy, which is in Phase 2a clinical trial for the treatment of the dry age-related macular degeneration; OPC1, an allogeneic oligodendrocyte progenitor cell therapy that is in Phase 1/2a multicenter clinical trial for the treatment of cervical spinal cord injuries; and VAC, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells, which is in Phase I clinical trial to treat non-small cell lung cancer. It also offers ANP1, an allogeneic auditory neuron progenitor cell transplant, which is in preclinical development for the treatment of debilitating hearing loss; and PNC1, an allogeneic photoreceptor cell transplant, which is in preclinical development for the treatment of vision loss due to photoreceptor dysfunction or damage.
Lineage Cell Therapeutics, Inc. Fundamentals Summary
| LCTX fundamental statistics | |
|---|---|
| Market cap | US$163.23m |
| Earnings (TTM) | -US$20.11m |
| Revenue (TTM) | US$8.72m |
19.0x
P/S Ratio-8.3x
P/E RatioIs LCTX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| LCTX income statement (TTM) | |
|---|---|
| Revenue | US$8.72m |
| Cost of Revenue | -US$2.31m |
| Gross Profit | US$11.03m |
| Other Expenses | US$31.14m |
| Earnings | -US$20.11m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.11 |
| Gross Margin | 126.54% |
| Net Profit Margin | -230.66% |
| Debt/Equity Ratio | 0% |
How did LCTX perform over the long term?
See historical performance and comparison